There are more than 40 mutual fund companies in India, providing more than 1,000 mutual fund schemes in different categories. Read on to find how many of that you should hold in your portfolio.

Be prepared for an eventful Friday with SGX Nifty indicating a gap-up start for the Indian markets with full of surprises for the participants. Chinese commerce ministry indicating that China and US are likely to hold trade talks in coming days have resulted in overnight change of sentiments all across the globe.

On the upside, the immediate resistance is at 11,370, followed by 11,400. As long as Nifty stays below this level, do not create any aggressive long positions. On the other hand, the range of 11,200-11,250 is likely to act as immediate support for the index. Stocks in news: GMM Pfaudler, Greenlam Industries, Hindalco Industries, TCS, Premier Explosives, Wipro.

The company reported consolidated net sales of Rs 152.33 crore in Q1FY21, which declined by 45.61 per cent YoY from Rs 280.07 crore in Q1FY20.

Net interest income (NII) stood at Rs 1412.32 crore which witnessed a growth of 9.6 per cent YoY, as against Rs 1289 crore it reported in Q1FY20. 

The stock of Acrysil Limited hit its upper circuit on Thursday after the company announced that it has entered into a strategic partnership with IKEA Supply AG (Switzerland) for manufacturing and supply of composite quartz kitchen sinks for their global requirement.

India’s largest carmaker, Maruti Suzuki India Limited, announced on Thursday that it has entered into a partnership with Nadathur S Raghavan Centre for Entrepreneurial Learning (NSRCEL), the startup hub and incubation centre at Indian Institute of Management, Bangalore (IIMB).

In the ranking for top lenders, State Bank of India (SBI), Canara Bank, Punjab National Bank (PNB), Bank of India, Union Bank of India, and HDFC Bank stood as leaders.

Infosys Ltd launched Infosys Cobalt, a set of services, solutions, & platforms that acts as a force multiplier for cloud-powered enterprise transformation on Thursday.

Cipla Limited announced on Thursday that its partner, Stempeutics Research Pvt Ltd has received regulatory approval by Drug Controller General of India (DCGI) for the launch of Stempeucel® in India.